Turner Syndrome Lifespan Management Gets a Major Evidence-Based Update

Turner syndrome (TS) is a chromosomal condition diagnosed in females with partial or complete loss of the second sex chromosome, occurring in approximately 1 in 2000-2500 live births. Despite its prevalence, median age of diagnosis remains around 15 years, with many individuals diagnosed even later—missing critical windows for growth hormone and estrogen therapy. This clinical review, anchored in recently published international practice guidelines, uses three detailed patient cases to provide a practical, lifespan-spanning management framework.

The first case—a 17-year-old with 45,X/46,XY mosaicism—illustrates the challenges of late diagnosis, the necessity of accurate karyotyping (examining at least 30 metaphases), and the management of Y chromosome material, which carries an 11-20% risk of gonadoblastoma. The updated guidelines move away from mandatory early gonadectomy toward an individualized, patient-centered approach weighing malignancy risk against potential gonadal function. Growth hormone therapy achieved a final height of 160 cm (vs. an untreated average deficit of ~20 cm), and transdermal 17-beta-estradiol successfully induced puberty and uterine growth.

The second and third cases (described in the full paper) address adult women facing cardiovascular surveillance and pregnancy-related risks. Cardiovascular disease is the leading cause of excess mortality in TS: bicuspid aortic valve occurs in ~30%, coarctation of the aorta in ~10%, and aortic dissection risk is substantially elevated. MRI-based aortic surveillance using the aortic size index is recommended, with surgical thresholds set lower than the general population. Hypertension must be aggressively managed. Women with TS considering pregnancy—whether via donor egg or spontaneous conception—require thorough pre-conception cardiac evaluation given the heightened risk of aortic dissection during pregnancy.

Beyond cardiovascular risk, TS carries significant burdens of autoimmune thyroid disease, celiac disease, type 1 and type 2 diabetes, osteoporosis, sensorineural hearing loss, renal structural anomalies, liver enzyme elevation, and neurocognitive challenges including difficulties with visuospatial processing and social cognition. The review provides a comprehensive comorbidity monitoring table covering eyes, ears, teeth, skin, kidneys, liver, metabolic health, and mental health, with recommended screening intervals across the lifespan.

Long-term hormone replacement therapy (HRT) is framed as essential for bone, cardiovascular, metabolic, and quality-of-life outcomes, with transdermal estradiol preferred and target serum estradiol levels of 100-150 pg/mL recommended in adults. Structured transition clinics involving endocrinology, cardiology, genetics, and psychology are advocated to prevent the well-documented loss to follow-up at the pediatric-to-adult care boundary. The authors call for neonatal screening and algorithm-based diagnostic tools to improve early detection rates.